Document:

<PAGE>

                                   Exhibit 4.9

                    Warrant to Shoreline Micro-Cap Fund, L.P.

THIS COMMON STOCK PURCHASE WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THE HOLDER HEREOF, BY PURCHASING
THIS COMMON STOCK PURCHASE WARRANT, AGREES FOR THE BENEFIT OF THE COMPANY THAT
SUCH SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED ONLY (A) TO THE
COMPANY, (B) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT, OR (C) IF REGISTERED UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE
SECURITIES LAWS.

                     ---------------------------------------

                             BOSTON BIOMEDICA, INC.

                          COMMON STOCK PURCHASE WARRANT

--------------------------------------------------------------------------------
                                          No. 5
Number of shares: 7,822                   Holder: Shoreline Micro-Cap Fund, L.P.
 Expiration Date: August 25, 2005         c/o William Blair & Company
                                          222 West Adams Street
                                          Chicago, IL 60606
                                          Attn: Richard P. Kiphart
Purchase Price Per Share:  $3.60

          For identification only. The governing terms of this Warrant
                              are set forth below.
--------------------------------------------------------------------------------

         Boston Biomedica, Inc., a Massachusetts corporation (the "COMPANY"),
hereby certifies that, for value received, Shoreline Micro-Cap Fund, L.P., or
its assigns (the "HOLDER"), is entitled, subject to the terms set forth below,
to purchase from the Company at any time or from time to time after the date
hereof and prior to the fifth anniversary hereof (the "EXERCISE PERIOD"), at the
Purchase Price hereinafter set forth, seven thousand eight hundred and
twenty-two (7,822) shares of the fully paid and nonassessable shares of common
stock of the Company, $0.01 par value per share (the "Common Stock"). The number
and character of such shares of Common Stock and the Purchase Price are subject
to adjustment as provided herein.

         The purchase price per share of Common Stock issuable upon exercise of
this Warrant (the "PURCHASE PRICE") shall initially be equal to 120% of the
average Closing Bid Price as published by Bloomberg, L.P. of the Common Stock on
the day immediately preceding the date hereof; PROVIDED, HOWEVER, that the
Purchase Price shall be adjusted from time to time as provided herein.

         Capitalized terms used herein not otherwise defined shall have the
meanings ascribed thereto in that certain Securities Purchase Agreement of even
date herewith between the Company, the

                                       1
<PAGE>

Holder and Richard T. Kiphart (the "Purchase Agreement"). By execution of this
Warrant, the Holder hereof agrees to be bound by and to benefit from the
provisions of the Purchase Agreement set forth herein. As used herein the
following terms, unless the context otherwise requires, have the following
respective meanings:

                  (a) The term "COMPANY" shall include Boston Biomedica, Inc.
         and any corporation that shall succeed or assume the obligations of
         such corporation hereunder.

                  (b) The term "COMMON STOCK" includes (a) the Company's common
         stock, par value $0.01 per share, (b) any other capital stock of any
         class or classes (however designated) of the Company, authorized on or
         after the date hereof, the Holders of which shall have the right,
         without limitation as to amount, either to all or to a share of the
         balance of current dividends and liquidating dividends after the
         payment of dividends and distributions on any shares entitled to
         preference, and the Holders of which shall ordinarily, in the absence
         of contingencies, be entitled to vote for the election of a majority of
         directors of the Company (even though the right so to vote has been
         suspended by the happening of such a contingency) and (c) any other
         securities into which or for which any of the securities described in
         (a) or (b) may be converted or exchanged pursuant to a plan of
         recapitalization, reorganization, merger, sale of assets or otherwise.

                  (c) The term "OTHER SECURITIES" refers to any stock (other
         than Common Stock) and other securities of the Company or any other
         person (corporate or otherwise) that the Holder of this Warrant at any
         time shall be entitled to receive, or shall have received, on the
         exercise of this Warrant, in lieu of or in addition to Common Stock, or
         that at any time shall be issuable or shall have been issued in
         exchange for or in replacement of Common Stock or Other Securities
         pursuant to Section 4 or otherwise.

         1.       EXERCISE OF WARRANT.

                  1.1      METHOD OF EXERCISE.

                  (a) This Warrant may be exercised in whole or in part (but not
         as to a fractional share of Common Stock), at any time and from time to
         time during the Exercise Period by the Holder hereof by delivery of a
         notice of exercise (a "NOTICE OF EXERCISE") substantially in the form
         attached hereto as EXHIBIT A via facsimile to the Company. Prior to
         sending the Notice of Exercise via facsimile, the Holder shall give
         Richard Schumacher notice of its intent to submit a Notice of Exercise
         by telephone (and if Mr. Schumacher is not available to be reached by
         telephone, either Kevin Quinlan or Kathi Benjamin by telephone, or such
         other person designated by the Company after the Closing Date).
         Promptly thereafter the Holder shall surrender this Warrant (if the
         entire amount of the Warrant is subject to the Notice of Exercise) to
         the Company at its principal office via overnight delivery service,
         accompanied by payment of the Purchase Price multiplied by the number
         of shares of Common Stock for which this Warrant is being exercised
         (the "EXERCISE PRICE"). Payment of the Exercise Price shall be made, at
         the option of the Holder, (i) by check or bank draft payable to the
         order of the Company, or (ii) by wire transfer to the account of the
         Company.

                                       2
<PAGE>

         Upon exercise, the Holder shall be entitled to receive within three
         Trading Days of the Exercise Date (as defined herein), one or more
         certificates, issued in the Holder's name or in such name or names as
         the Holder may direct, subject to the limitations on transfer contained
         herein, for the number of shares of Common Stock so purchased. The
         shares of Common Stock so purchased shall be deemed to be issued as of
         the close of business on the date on which the Company shall have
         received from the Holder payment in full of the Exercise Price (the
         "EXERCISE DATE").

                  (b) Upon exercise of a portion of this Warrant in accordance
         with the terms hereof, records showing the amount so exercised and the
         date of exercise shall be maintained on a ledger substantially in the
         form of ANNEX B attached hereto (an originally signed and executed copy
         of which shall be delivered to the Company with each Notice of
         Exercise). The Company shall maintain the originally signed and
         executed ledger and the Holder shall maintain a copy thereof. Upon
         execution of the exercise of the Warrants contemplated by the Notice of
         Exercise, the Company shall deliver to the Holder a copy of ANNEX B
         signed and executed by the Company, and the Holder shall deliver to the
         Company a copy of Annex B signed by the Holder. It is specifically
         contemplated that the Company shall act as the calculation agent for
         all exercises of this Warrant. The Holder and any assignee, by
         acceptance of this Warrant, acknowledges and agrees that, by reason of
         the provisions of this paragraph, following an exercise of a portion of
         this Warrant, the number of shares of Common Stock represented by this
         Warrant will be the amount indicated on ANNEX B attached hereto (which
         may be less than the amount stated on the face hereof).

                  (c) In the event there is a dispute as to the number of shares
         of Common Stock the Holder is entitled to receive upon exercise of this
         Warrant, the Company shall issue to the Holder the number of shares not
         in dispute and the Company and the Holder will use their best efforts
         to resolve such dispute within one Business Day following the receipt
         of a Notice of Exercise. If such dispute cannot be resolved within such
         one-day period, the Company and the Holder shall submit the dispute to
         an independent accountant mutually agreed upon by the Company and the
         Holder to make a final and binding determination of the number of
         shares owed to the Holder. The Company shall issue shares of Common
         Stock owed to Holder as a result of the resolution of the dispute
         within two Business Days following the receipt of the accountant's
         independent determination.

                  1.2 REGULATION D RESTRICTIONS. The Holder hereof represents
and warrants to the Company that it has acquired this Warrant and anticipates
acquiring the shares of Common Stock issuable upon exercise of the Warrant
solely for its own account for investment purposes and not with a view to or for
resale of such securities unless such resale has been registered with the
Commission or an applicable exemption is available therefor and provided that
the Holder shall have furnished to the Company an opinion of counsel in form and
substance reasonably satisfactory to the Company, to the effect that such
transfer is exempt from the registration requirements of the Securities Act and
any applicable state securities laws.

                  1.3 COMPANY ACKNOWLEDGMENT. The Company will, at the time of
the exercise of this Warrant, upon request of the Holder hereof, acknowledge in
writing its continuing obligation

                                       3
<PAGE>

to afford to such Holder the registration rights to which such Holder shall
continue to be entitled after such exercise in accordance with the provisions of
a Registration Rights Agreement dated the date hereof (the "Registration Rights
Agreement").

                  1.4 LIMITATION ON EXERCISE. Notwithstanding the rights of the
Holder to exercise all or a portion of this Warrant as described herein, such
exercise rights shall be limited, solely to the extent set forth in the Purchase
Agreement as if such provisions were specifically set forth herein. In addition,
the number of shares of Common Stock issuable upon exercise of this Warrant is
subject to reduction as specified in Section 10.3 of the Purchase Agreement.

         2. DELIVERY OF STOCK CERTIFICATES, ETC., ON EXERCISE. As soon as
practicable after the exercise of this Warrant, and in any event within three
(3) Business Days thereafter, the Company at its expense (including the payment
by it of any applicable issue, stamp or transfer taxes) will cause to be issued
in the name of and delivered to the Holder thereof, or, to the extent
permissible hereunder, to such other person as such Holder may direct, a
certificate or certificates for the number of fully paid and nonassessable
shares of Common Stock (or Other Securities) to which such Holder shall be
entitled on such exercise, plus, in lieu of any fractional share to which such
Holder would otherwise be entitled, cash equal to such fraction multiplied by
the then applicable Purchase Price, together with any other stock or other
securities and property (including cash, where applicable) to which such Holder
is entitled upon such exercise pursuant to Section 1 or otherwise.

         3. ADJUSTMENT FOR EXTRAORDINARY EVENTS. The Purchase Price to be paid
by the Holder upon exercise of this Warrant, and the consideration to be
received upon exercise of this Warrant, shall be adjusted in case at any time or
from time to time pursuant to Article 11 of the Purchase Agreement as if such
provisions were specifically set forth herein.

         4. NO IMPAIRMENT. The Company will not, by amendment of its Certificate
of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the
carrying out of all such terms and in the taking of all such action as may be
necessary or appropriate in order to protect the rights of the Holder of this
Warrant against impairment. Without limiting the generality of the foregoing,
the Company (a) will not increase the par value of any shares of stock
receivable on the exercise of this Warrant above the amount payable therefor on
such exercise, (b) will take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and
unassessable shares of stock on the exercise of this Warrant, and (c) will not
transfer all or substantially all of its properties and assets to any other
person (corporate or otherwise), or consolidate with or merge into any other
person or permit any such person to consolidate with or merge into the Company
(if the Company is not the surviving person), unless such other person shall
expressly assume in writing and will be bound by all the terms of this Warrant.

         5. CERTIFICATE AS TO ADJUSTMENTS. In each case of any adjustment or
readjustment in the shares of Common Stock (or Other Securities) issuable on the
exercise of this Warrant, the Company will promptly cause its principal
financial officer to compute such adjustment or readjustment in

                                       4
<PAGE>

accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment or readjustment and showing in detail the facts upon which
such adjustment or readjustment is based, including a statement of (a) the
consideration received or receivable by the Company for any additional shares of
Common Stock (or Other Securities) issued or sold or deemed to have been issued
or sold, (b) the number of shares of Common Stock (or Other Securities)
outstanding or deemed to be outstanding, and (c) the Purchase Price and the
number of shares of Common Stock to be received upon exercise of this Warrant,
in effect immediately prior to such issue or sale and as adjusted and readjusted
as provided in this Warrant. The Company will forthwith mail a copy of each such
certificate to the Holder of this Warrant, and will, on the written request at
any time of the Holder of this Warrant, furnish to such Holder a like
certificate setting forth the Purchase Price at the time in effect and showing
how it was calculated.

         6. NOTICES OF RECORD DATE, ETC.

            In the event of

                           (a) any taking by the Company of a record of the
         Holders of any class of securities for the purpose of determining the
         Holders thereof who are entitled to receive any dividend or other
         distribution, or any right to subscribe for, purchase or otherwise
         acquire any shares of stock of any class or any other securities or
         property, or to receive any other right, or

                           (b) any capital reorganization of the Company, any
         reclassification or recapitalization of the capital stock of the
         Company or any transfer of all or substantially all the assets of the
         Company to or consolidation or merger of the Company with or into any
         other Person, or

                           (c) any voluntary or involuntary dissolution,
         liquidation or winding-up of the Company,

then and in each such event the Company will mail or cause to be mailed to the
Holder of this Warrant a notice specifying (i) the date on which any such record
is to be taken for the purpose of such dividend, distribution or right, and
stating the amount and character of such dividend, distribution or right, and
(ii) the date on which any such reorganization, reclassification,
recapitalization, transfer, consolidation, merger, dissolution, liquidation or
winding-up is to take place, and the time, if any, as of which the Holders of
record of Common Stock (or Other Securities) shall be entitled to exchange their
shares of Common Stock (or Other Securities) for securities or other property
deliverable on such reorganization, reclassification, recapitalization,
transfer, consolidation, merger, dissolution, liquidation or winding-up. Such
notice shall be mailed at least 20 days prior to the date specified in such
notice on which any action is to be taken.

         7. RESERVATION OF STOCK, ETC. ISSUABLE ON EXERCISE OF WARRANT. The
Company will at all times reserve and keep available, solely for issuance and
delivery on the exercise of this Warrant, all shares of Common Stock (or Other
Securities) from time to time issuable on the exercise of this Warrant.

                                       5
<PAGE>

         8. EXCHANGE OF WARRANT. On surrender for exchange of this Warrant,
properly endorsed and in compliance with the restrictions on transfer set forth
in the legend on the face of this Warrant, to the Company, the Company at its
expense will issue and deliver to or on the order of the Holder thereof a new
Warrant of like tenor, in the name of such Holder or as such Holder (on payment
by such Holder of any applicable transfer taxes) may direct, calling in the
aggregate on the face or faces thereof for the number of shares of Common Stock
called for on the face of the Warrant so surrendered or for such lesser number
of shares of Common Stock as may be reflected on the Warrant Exercise Ledger
attached as Annex B.

         9. REPLACEMENT OF WARRANT. On receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction of this
Warrant, on delivery of an indemnity agreement or security reasonably
satisfactory in form and amount to the Company or, in the case of any such
mutilation, on surrender and cancellation of this Warrant, the Company at its
expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

         10. REMEDIES. The Company stipulates that the remedies at law of the
Holder of this Warrant in the event of any default or threatened default by the
Company in the performance of or compliance with any of the terms of this
Warrant are not and will not be adequate, and that such terms may be
specifically enforced by a decree for the specific performance of any agreement
contained herein or by an injunction against a violation of any of the terms
hereof or otherwise.

         11. NEGOTIABILITY, ETC.. This Warrant is issued upon the following
terms, to all of which each Holder or owner hereof by the taking hereof consents
and agrees:

                   (a) until this Warrant is transferred on the books of the
Company, the Company may treat the registered Holder hereof as the absolute
owner hereof for all purposes, notwithstanding any notice to the contrary; and

                  (b) this Warrant may not be sold, transferred or assigned
except pursuant to an effective registration statement under the Securities Act
or pursuant to an applicable exemption therefrom.

         12. REGISTRATION RIGHTS. The Company is obligated to register the
shares of Common Stock issuable upon exercise of this Warrant in accordance with
the terms of the Registration Rights Agreement.

         13. WARRANT REDEMPTION. Upon occurrence of the events described in
Sections 3.4 and 10.4(c) of the Purchase Agreement, the Company, at the request
of Holder, shall redeem all outstanding Warrants that remain unexercised at a
redemption price equal to the greater of (x) an appraised value of the Warrants,
as determined by Black Sholes, on the date they are called for redemption and
(y) the number of Warrants being redeemed multiplied by the excess of (A) the
average Closing Bid Price of the Common Stock for the five trading days
immediately prior to the date that the Warrants are called for redemption over
(B) the exercise price of the Warrants.

                                       6
<PAGE>

         14. NOTICES, ETC. All notices and other communications from the Company
to the Holder of this Warrant shall be mailed by first class registered or
certified mail, postage prepaid, at such address as may have been furnished to
the Company in writing by such Holder or, until any such Holder furnishes to the
Company any address, then to, and at the address of, the last Holder of this
Warrant who has so furnished an address to the Company.

         15. MISCELLANEOUS. This Warrant and any term hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination
is sought. This Warrant shall be construed and enforced in accordance with and
governed by the internal laws of the State of Massachusetts. The headings in
this Warrant are for the purposes of reference only, and shall not limit or
otherwise affect any of the terms hereof. The invalidity or unenforceability of
any provision hereof shall in no way affect the validity or enforceability of
any other provision.

                                       7
<PAGE>

                       SIGNATURE PAGE TO SHORELINE WARRANT

    DATED as of August 25, 2000.

                                             BOSTON BIOMEDICA, INC.

                                             By: /s/ Kevin W. Quinlan
                                             Name: Kevin W. Quinlan
                                             Title: President

                                       8
<PAGE>

                                    EXHIBIT A
                        FORM OF NOTICE EXERCISE - WARRANT
                       (To be executed only upon exercise
                       of the Warrant in whole or in part)

To ____________________________________________

       The undersigned registered Holder of the accompanying Warrant, hereby

exercises such Warrant or portion thereof for, and purchases thereunder,
__________(1) shares of Common Stock (as defined in such Warrant) and herewith
makes payment therefor in the amount and manner set forth below, as of the date
written below. The undersigned requests that the certificates for such shares of
Common Stock be issued in the name of, and delivered to,___________________
whose address is ________________________________________________________.

       The Exercise Price is paid as follows:

 / / Certified Bank draft payable to the Company in the amount of $____________.
 / / Wire transfer to the account of the Company in the amount of $___________.

       Upon exercise pursuant to this Notice of Exercise, the Holder will be in
compliance with the Limitation on Exercise (as defined in the Securities
Purchase Agreement pursuant to which this Warrant was issued).

       The Holder of the shares of Common Stock received upon exercise of the
Warrant (the "Common Shares"), covenants and agrees that the Common Shares are
being acquired as an investment and not with a view to the distribution thereof
in violation of the Securities Act and that the Common Shares may not be
transferred, sold, assigned, hypothecated or otherwise disposed of, in whole or
in part except as provided in the legend on the first page of this Warrant and
provided that the Holder shall have furnished the Company an opinion of counsel
in form and substance reasonably acceptable to the Company to the effect that
such transfer is exempt from the registration requirements of the Securities Act
and any applicable state securities laws.*

Date:_____________________________     _________________________________________
                                       (Name must conform to name of Holder as
                                       specified on the face of the Warrant)
                                       By:______________________________________
                                          Name:_________________________________
                                          Title:________________________________
                                       Address of Holder:_______________________
                                                 _______________________________
                                                 _______________________________
Date of exercise:__________________________

*        If shares of common Stock are to be issued to anyone other than the
         Holder, this covenant and representation must be made by such other
         Person.

-----------------------------
         (1)Insert the number of shares of Common Stock as to which the
accompanying Warrant is being exercised. In the case of a partial exercise, a
new Warrant or Warrants will be issued and delivered, representing the
unexercised portion of the accompanying Warrant, to the Holder surrendering the
same.

<PAGE>

                                     ANNEX B

                             WARRANT EXERCISE LEDGER

<TABLE>
<CAPTION>

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------
                    ORIGINAL NUMBER OF       WARRANTS       EXERCISE PRICE    NEW BALANCE     ISSUER             HOLDER
      DATE               WARRANTS            EXERCISED           PAID         OF WARRANTS    INITIALS           INITIALS
----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------
<S>               <C>                      <C>            <C>                <C>           <C>            <C>

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------

----------------- ------------------------ -------------- ------------------ ------------- -------------- ---------------------

</TABLE>

BOSTON BIOMEDICA, INC.                           HOLDER:

By: _______________________                      By: ____________________
Name: _______________________                    Name:__________________
Title: ________________________                  Title:___________________<PAGE>

                                  Exhibit 4.10

                          Registration Rights Agreement

                          REGISTRATION RIGHTS AGREEMENT

         REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of August
25, 2000, between Boston Biomedica, Inc., a Massachusetts corporation (the
"Company"), and Richard P. Kiphart ("Kiphart") and Shoreline Micro-Cap Fund,
L.P. ("Shoreline").

         1.       INTRODUCTION.

                  1.1      SECURITIES PURCHASE AGREEMENT. The Company, Kiphart
and Shoreline as of the date hereof executed that certain Securities Purchase
Agreement (the "Securities Purchase Agreement"), pursuant to which the Company
has agreed, among other things, to issue up to an aggregate of One Million
Dollars ($1,000,000.00) (U.S.) principal amount of 3% Senior Subordinated
Convertible Debentures of the Company (the "Debentures") to Kiphart and
Shoreline or its successors, assigns or transferees (collectively, the
"holders"). The Debentures are convertible into an indeterminable number of
shares (the "Debenture Conversion Shares") of the Company's common stock par
value, $0.01 per share (the "Common Stock") pursuant to the terms of the
Debentures. In addition, pursuant to the terms of the Securities Purchase
Agreement and the transactions contemplated thereby, the Company has agreed to
issue to the Kiphart common stock purchase warrants exercisable for up to an
aggregate of 27,734 shares of the Company's Common Stock and common stock
purchase warrants exercisable for up to an aggregate of 7,822 shares of Common
Stock to Shoreline (collectively the "Warrant Shares"). The number of Debenture
Conversion Shares and Warrant Shares is subject to adjustment upon the
occurrence of stock splits, recapitalizations and similar events occurring after
the date hereof. Collectively, Shoreline and Kiphart are sometimes referred to
herein as the "Investors."

                  1.2      DEFINITION OF SECURITIES. The Debenture Conversion
Shares and the Warrant Shares are herein referred to as the "Securities."

                  1.3      NATIONAL MARKET REPRESENTATION. The Company
represents and warrants that the Company's Common Stock is currently eligible
for trading on the Nasdaq National Market under the symbol "BBII." Certain
capitalized terms used in this Agreement are defined in Section 3 hereof;
references to sections shall be to sections of this Agreement.

         2.       REGISTRATION UNDER SECURITIES ACT, ETC.

                  2.1      MANDATORY REGISTRATION.

                           (a)      REGISTRATION OF REGISTRABLE SECURITIES. The
Company shall prepare and file on or before the 30th day following the date
hereof (the "Filing Date") a registration statement (the "Registration
Statement") covering the resale of the Registrable Securities. The Company shall
use its best efforts to cause the Registration Statement to be declared
effective by the

<PAGE>

Commission on the earlier of (i) 90 days following the date hereof, (ii) ten
(10) days following the receipt of a "No Review" or similar letter from the
Commission or (iii) the first business day following the day the Commission
determines the Registration Statement eligible to be declared effective (the
"Required Effectiveness Date"). Nothing contained herein shall be deemed to
limit the number of Registrable Securities to be registered by the Company
hereunder. As a result, should the Registration Statement not relate to the
maximum number of Registrable Securities acquired by (or potentially acquirable
by) the holders thereof upon conversion of the Debentures, or exercise of the
Common Stock Purchase Warrants described in Section 1 above, the Company shall
be required to promptly file a separate registration statement (utilizing Rule
462 promulgated under the Securities Act, where applicable) relating to such
Registrable Securities which then remain unregistered. The provisions of this
Agreement shall relate to any such Registration Statement and any such separate
registration statement as if it were an amendment to the Registration Statement.

                           (b)      REGISTRATION STATEMENT FORM. Registrations
under this Section 2.1 shall be on Form S-3 or such other appropriate successor
registration form of the Commission as shall permit the disposition of such
Registrable Securities in accordance with the intended method or methods of
disposition specified by the Investors; provided, however, such intended method
of deposition shall not include an underwritten offering of the Registrable
Securities.

                           (c)      EXPENSES. The Company will pay all
Registration Expenses in connection with any registration required by this
Section 2.1.

                           (d)      EFFECTIVE REGISTRATION STATEMENT. A
registration pursuant to this Section 2.1 shall not be deemed to have been
effected (i) unless a registration statement with respect thereto has become
effective within the time period specified herein, provided that a registration
which does not become effective after the Company filed a registration statement
with respect thereto solely by reason of the refusal to proceed of any holder of
Registrable Securities (other than a refusal to proceed based upon the advice of
counsel in the form of a letter signed by such counsel and provided to the
Company relating to a disclosure matter unrelated to such holder) shall be
deemed to have been effected by the Company unless the holders of the
Registrable Securities shall have elected to pay all Registration Expenses in
connection with such registration, (ii) if, after it has become effective, such
registration becomes subject to any stop order, injunction or other order or
extraordinary requirement of the Commission or other governmental agency or
court for any reason or (iii) if, after it has become effective, such
registration ceases to be effective for more than an aggregate of twenty (20)
days.

                           (e)      PLAN OF DISTRIBUTION. The Company hereby
agrees that the Registration Statement shall include a plan of distribution
section reasonably acceptable to the Investors; provided, however, such plan of
distribution section shall be modified by the Company so as to not provide for
the disposition of the Registrable Securities on the basis of an underwritten
offering.

                  2.2      INCIDENTAL REGISTRATION.

                           (a)      RIGHT TO INCLUDE REGISTRABLE SECURITIES. If
at any time after the date hereof but before the third anniversary of the date
hereof, the Company proposes to register any of

                                       2

<PAGE>

its securities under the Securities Act (other than by a registration in
connection with an acquisition in a manner which would not permit registration
of Registrable Securities for sale to the public, on Form S-8, or any successor
form thereto, on Form S-4, or any successor form thereto and other than pursuant
to Section 2.1), on an underwritten basis (either best-efforts or
firm-commitment), then, the Company will each such time give prompt written
notice to all holders of Registrable Securities of its intention to do so and of
such holders' rights under this Section 2.2. Upon the written request of any
such holder made within twenty (20) days after the receipt of any such notice
(which request shall specify the Registrable Securities intended to be disposed
of by such holder and the intended method of disposition thereof), the Company
will, subject to the terms of this Agreement, use its commercially reasonable
best efforts to effect the registration under the Securities Act of the
Registrable Securities, to the extent requisite to permit the disposition (in
accordance with the intended methods thereof as aforesaid) of such Registrable
Securities so to be registered, by inclusion of such Registrable Securities in
the registration statement which covers the securities which the Company
proposes to register, provided that if, at any time after written notice of its
intention to register any securities and prior to the effective date of the
registration statement filed in connection with such registration, the Company
shall determine for any reason either not to register or to delay registration
of such securities, the Company may, at its election, give written notice of
such determination to each holder and, thereupon, (i) in the case of a
determination not to register, shall be relieved of this obligation to register
any Registrable Securities in connection with such registration (but not from
its obligation to pay the Registration Expenses in connection therewith), and
(ii) in the case of a determination to delay registering, shall be permitted to
delay registering any Registrable Securities, for the same period as the delay
in registering such other securities. No registration effected under this
Section 2.2 shall relieve the Company of its obligation to effect any
registration under Section 2.1, nor shall any such registration hereunder be
deemed to have been effected pursuant to Section 2.1. The Company will pay all
Registration Expenses in connection with each registration of Registrable
Securities requested pursuant to this Section 2.2. The right provided the
holders of the Registrable Securities pursuant to this Section shall be
exercisable at their sole discretion.

                           (b)      PRIORITY IN INCIDENTAL REGISTRATIONS. If the
managing underwriter of the underwritten offering contemplated by this Section
2.2 shall inform the Company and holders of the Registrable Securities
requesting such registration by letter of its belief that the number of
securities requested to be included in such registration exceeds the number
which can be sold in such offering, then the Company will include in such
registration, to the extent of the number which the Company is so advised can be
sold in such offering, (i) first securities proposed by the Company to be sold
for its own account, and (ii) second Registrable Securities and securities of
other selling security holders requested to be included in such registration pro
rata on the basis of the number of shares of such securities so proposed to be
sold and so requested to be included; provided, however, the holders of
Registrable Securities shall have priority to all shares sought to be included
by officers and directors of the Company as well as holders of ten percent (10%)
or more of the Company's Common Stock.

                  2.3      REGISTRATION PROCEDURES. If and whenever the Company
is required to effect the registration of any Registrable Securities under the
Securities Act as provided in Section 2.1 and, as applicable, 2.2, the Company
shall, as expeditiously as possible:

                                       3

<PAGE>

                           (a)      prepare and file with the Commission the
Registration Statement or amendments thereto, to effect such registration
(including such audited financial statements as may be required by the
Securities Act or the rules and regulations promulgated thereunder) and
thereafter use its commercially reasonable best efforts to cause such
registration statement to be declared effective by the Commission, as soon as
practicable, but in any event no later than the Required Effectiveness Date
(with respect to a registration pursuant to Section 2.1); provided, however,
that before filing such registration statement or any amendments thereto, the
Company will furnish to the counsel selected by the holders of Registrable
Securities which are to be included in such registration, copies of all such
documents proposed to be filed;

                           (b)      with respect to any registration statement
pursuant to Section 2.1, prepare and file with the Commission such amendments
and supplements to such registration statement and the prospectus used in
connection therewith as may be necessary to keep such registration statement
effective and to comply with the provisions of the Securities Act with respect
to the disposition of all Registrable Securities covered by such registration
statement until the earlier to occur of five (5) years after the date of this
Agreement (subject to the right of the Company to suspend the effectiveness
thereof for not more than 10 consecutive days or an aggregate of 30 days in such
five (5) years period) or such time as all of the securities which are the
subject of such registration statement cease to be Registrable Securities (such
period, in each case, the "Registration Maintenance Period");

                           (c)      furnish to each seller of Registrable
Securities covered by such registration statement such number of conformed
copies of such registration statement and of each such amendment and supplement
thereto (in each case including all exhibits), such number of copies of the
prospectus contained in such registration statement (including each preliminary
prospectus and any summary prospectus) and any other prospectus filed under Rule
424 under the Securities Act, in conformity with the requirements of the
Securities Act, and such other documents, as such seller and underwriter, if
any, may reasonably request in order to facilitate the public sale or other
disposition of the Registrable Securities owned by such seller;

                           (d)      use its commercially reasonable best efforts
to register or qualify all Registrable Securities and other securities covered
by such registration statement under such other securities laws or blue sky laws
as any seller thereof shall reasonably request, to keep such registrations or
qualifications in effect for so long as such registration statement remains in
effect, and take any other action which may be reasonably necessary to enable
such seller to consummate the disposition in such jurisdictions of the
securities owned by such seller, except that the Company shall not for any such
purpose be required to qualify generally to do business as a foreign corporation
in any jurisdiction wherein it would not but for the requirements of this
subdivision (d) be obligated to be so qualified or to consent to general service
of process in any such jurisdiction;

                           (e)      use its commercially reasonable best efforts
to cause all Registrable Securities covered by such registration statement to be
registered with or approved by such other governmental agencies or authorities
as may be necessary to enable the seller or sellers thereof to consummate the
disposition of such Registrable Securities;

                                       4

<PAGE>

                           (f)      furnish to each seller of Registrable
Securities a signed counterpart, addressed to such seller, and the underwriters,
if any, of:

                                    (1)      an opinion of counsel for the
Company, dated the effective date of such registration statement (or, if such
registration includes an underwritten public offering, an opinion dated the date
of the closing under the underwriting agreement), reasonably satisfactory in
form and substance to such seller including that the prospectus and any
prospectus supplement forming a part of the Registration Statement does not
contain an untrue statement of a material fact or omits a material fact required
to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading, and

                                    (2)      if such registration includes an
underwritten public offering, a "comfort letter" dated the date of the closing
and required to be delivered to the underwriter under the underwriting
agreement, signed by the independent public accountants who have certified the
Company's financial statements;

                           (g)      notify the Sellers' Representative and its
counsel promptly and confirm such advice in writing promptly after the Company
has knowledge thereof:

                                    (1)      when the Registration Statement,
the prospectus or any prospectus supplement related thereto or post-effective
amendment to the Registration Statement has been filed, and, with respect to the
Registration Statement or any post-effective amendment thereto, when the same
has become effective;

                                    (2)      of any request by the Commission
for amendments or supplements to the Registration Statement or the prospectus or
for additional information;

                                    (3)      of the issuance by the Commission
of any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings by any Person for that purpose; and

                                    (4)      of the receipt by the Company of
any notification with respect to the suspension of the qualification of any
Registrable Securities for sale under the securities or blue sky laws of any
jurisdiction or the initiation or threat of any proceeding for such purpose;

                           (h)      notify each seller of Registrable Securities
covered by such registration statement, at any time when a prospectus relating
thereto is required to be delivered under the Securities Act, upon discovery
that, or upon the happening of any event as a result of which, the prospectus
included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state any material facts required to be
stated therein or necessary to make the statements therein not misleading in the
light of the circumstances then existing, and at the request of any such seller
promptly prepare and furnish to such seller a reasonable number of copies of a
supplement to or an amendment of such prospectus as may be necessary so that, as
thereafter delivered to the purchasers of such securities, such prospectus shall

                                       5

<PAGE>

not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein
not misleading in the light of the circumstances then existing;

                           (i)      use its commercially reasonable best efforts
to obtain the withdrawal of any order suspending the effectiveness of the
Registration Statement at the earliest possible moment;

                           (j)      otherwise use its commercially reasonable
best efforts to comply with all applicable rules and regulations of the
Commission, and make available to its security holders, as soon as reasonably
practicable, an earnings statement covering the period of at least twelve
months, but not more than eighteen months, beginning with the first full
calendar month after the effective date of such registration statement, which
earnings statement shall satisfy the provisions of Section 11(a) of the
Securities Act and Rule 158 thereunder;

                           (k)      use its commercially reasonable best efforts
to list all Registrable Securities covered by such registration statement on any
securities exchange on which any of the Registrable Securities are then listed.

         The Company may require each seller of Registrable Securities as to
which any registration is being effected to furnish the Company such information
regarding such seller and the distribution of such securities as the Company may
from time to time reasonably request in writing.

         The Company will not file any registration statement pursuant to
Section 2.1, or amendment thereto or any prospectus or any supplement thereto
(including such documents incorporated by reference and proposed to be filed
after the initial filing of the Registration Statement) to which the Sellers'
Representative shall reasonably object, provided that the Company may file such
documents in a form required by law or upon the advice of its counsel.

         The Company represents and warrants to each holder of Registrable
Securities that it has obtained all necessary waivers, consents and
authorizations necessary to execute this Agreement and consummate the
transactions contemplated hereby other than such waivers, consents and/or
authorizations specifically contemplated by the Securities Purchase Agreement.

         The Investors agree that, upon receipt of any notice from the Company
of the occurrence of any event of the kind described in subdivision (h) of this
Section 2.3, the Investors will forthwith discontinue the Investors' disposition
of Registrable Securities pursuant to the Registration Statement relating to
such Registrable Securities until such Investors' receipt of the copies of the
supplemented or amended prospectus contemplated by subdivision (h) of this
Section 2.3 and, if so directed by the Company, will deliver to the Company (at
the Company's expense) all copies, other than permanent file copies, then in the
Investors' possession of the prospectus relating to such Registrable Securities
current at the time of receipt of such notice.

                  2.4      UNDERWRITTEN OFFERINGS.

                                       6

<PAGE>

                           (a)      INCIDENTAL UNDERWRITTEN OFFERINGS. If the
Company at any time proposes to register any of its securities under the
Securities Act as contemplated by Section 2.2 and such securities are to be
distributed by or through one or more underwriters, the Company will, if
requested by any holder of Registrable Securities as provided in Section 2.2 and
subject to the provisions of Section 2.2(a), use its commercially reasonable
best efforts to arrange for such underwriters to include all the Registrable
Securities to be offered and sold by such holder among the securities to be
distributed by such underwriters.

                           (b)      HOLDBACK AGREEMENTS. Subject to such other
reasonable requirements as may be imposed by the underwriter as a condition of
inclusion of holder's Registrable Securities in the registration statement, each
holder agrees by acquisition of Registrable Securities, if so required by the
managing underwriter, not to sell, make any short sale of, loan, grant any
option for the purchase of, effect any public sale or distribution of or
otherwise dispose of, except as part of such underwritten registration, any
equity securities of the Company, during such reasonable period of time
requested by the underwriter; provided however, such period shall not exceed the
150 day period commencing 30 days prior to the commencement of such underwritten
offering and ending 120 days following the completion of such underwritten
offering.

                           (c)      PARTICIPATION IN UNDERWRITTEN OFFERINGS. No
holder of Registrable Securities may participate in any underwritten offering
under Section 2.2 unless such holder of Registrable Securities (i) agrees to
sell such Person's securities on the basis provided in any underwriting
arrangements approved, subject to the terms and conditions hereof, approved by
the Company and (ii) completes and executes all questionnaires, indemnities,
underwriting agreements and other documents (other than powers of attorney)
required under the terms of such underwriting arrangements. Notwithstanding the
foregoing, no underwriting agreement (or other agreement in connection with such
offering) shall require any holder of Registrable Securities to make any
representations or warranties to or agreements with the Company or the
underwriters other than representations and warranties contained in a writing
furnished by such holder expressly for use in the related registration statement
or representations, warranties or agreements regarding such holder, such
holder's Registrable Securities and such holder's intended method of
distribution and any other representation required by law.

                  2.5      PREPARATION; REASONABLE INVESTIGATION. In connection
with the preparation and filing of each registration statement under the
Securities Act pursuant to this Agreement, the Company will give Sellers'
Representative and counsel and accountants for Sellers' Representative, the
opportunity to participate in the preparation of such registration statement,
each prospectus included therein or filed with the Commission, and each
amendment thereof or supplement thereto, and will give each of them such access
to its books and records and such opportunities to discuss the business of the
Company with its officers and the independent public accountants who have
certified its financial statements as shall be necessary, in the reasonable
opinion of such holders' and such underwriters' respective counsel, to conduct a
reasonable investigation within the meaning of the Securities Act.

                  2.6      REGISTRATION DEFAULT FEE. If the Registration
Statement contemplated in Section 2.1 is (x) not declared effective by the
Required Effectiveness Date or (y) such effectiveness

                                       7

<PAGE>

is not maintained for the Registration Maintenance Period, then the Company
shall pay to the Investors the Default Fee specified in Section 10.4 of the
Securities Purchase Agreement.

                  2.7      INDEMNIFICATION.

                  (a)      INDEMNIFICATION BY THE COMPANY. In the event of any
registration of any securities of the Company under the Securities Act, the
Company will, and hereby does agree to indemnify and hold harmless the holder of
any Registrable Securities covered by such registration statement, its directors
and officers, each other Person who participates as an underwriter in the
offering or sale of such securities and each other Person, if any, who controls
such holder or any such underwriter within the meaning of the Securities Act
against any losses, claims, damages or liabilities, joint or several, to which
such holder or any such director or officer or underwriter or controlling person
may become subject under the Securities Act or otherwise, insofar as such
losses, claims, damages or liabilities (or actions or proceedings, whether
commenced or threatened, in respect thereof) arise out of or are based upon any
untrue statement or alleged untrue statement of any material fact contained in
any registration statement under which such securities were registered under the
Securities Act, any preliminary prospectus, final prospectus or summary
prospectus contained therein, or any amendment or supplement thereto, or any
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, and
the Company will reimburse such holder and each such director, officer,
underwriter and controlling person for any legal or any other expenses
reasonably incurred by them in connection with investigating or defending any
such loss, claim, liability, action or proceeding, provided that the Company
shall not be liable in any such case to the extent that any such loss, claim,
damage, liability, (or action or proceeding in respect thereof) or expense
arises out of or is based upon an untrue statement or alleged untrue statement
or omission or alleged omission made in such registration statement, any such
preliminary prospectus, final prospectus, summary prospectus, amendment or
supplement in reliance upon and in conformity with written information furnished
to the Company by such holder or underwriter stating that it is for use in the
preparation thereof and, provided further that the Company shall not be liable
to any Person who participates as an underwriter in the offering or sale of
Registrable Securities or to any other Person, if any, who controls such
underwriter within the meaning of the Securities Act, in any such case to the
extent that any such loss, claim, damage, liability (or action or proceeding in
respect thereof) or expense arises out of such Person's failure to send or give
a copy of the final prospectus, as the same may be then supplemented or amended,
within the time required by the Securities Act to the Person asserting the
existence of an untrue statement or alleged untrue statement or omission or
alleged omission at or prior to the written confirmation of the sale of
Registrable Securities to such Person if such statement or omission was
corrected in such final prospectus or an amendment or supplement thereto. Such
indemnity shall remain in full force and effect regardless of any investigation
made by or on behalf of such holder or any such director, officer, underwriter
or controlling person and shall survive the transfer of such securities by such
holder.

                  (b)      INDEMNIFICATION BY THE HOLDERS. The Company may
require, as a condition to including any Registrable Securities in any
registration statement filed pursuant to this Agreement, that the Company shall
have received an undertaking satisfactory to it from the prospective seller of
such Registrable Securities, to indemnify and hold harmless (in the same

                                       8

<PAGE>

manner and to the same extent as set forth in subdivision (a) of this Section
2.7) the Company, each director of the Company, each officer of the Company and
each other Person, if any, who controls the Company within the meaning of the
Securities Act, with respect to any statement or alleged statement in or
omission or alleged omission from such registration statement, any preliminary
prospectus, final prospectus or summary prospectus contained therein, or any
amendment or supplement thereto, if such statement or alleged statement or
omission or alleged omission was made in reliance upon and in conformity with
written information furnished to the Company through an instrument duly executed
by such seller specifically stating that it is for use in the preparation of
such registration statement, preliminary prospectus, final prospectus, summary
prospectus, amendment or supplement. Any such indemnity shall remain in full
force and effect, regardless of any investigation made by or on behalf of the
Company or any such director, officer or controlling person and shall survive
the transfer of such securities by such seller.

                  (c)      NOTICES OF CLAIMS, ETC. Promptly after receipt by an
indemnified party of notice of the commencement of any action or proceeding
involving a claim referred to in the preceding subdivisions of this Section 2.7,
such indemnified party will, if a claim in respect thereof is to be made against
an indemnifying party, give written notice to the latter of the commencement of
such action, provided that the failure of any indemnified party to give notice
as provided herein shall not relieve the indemnifying party of its obligations
under the preceding subdivisions of this Section 2.7, except to the extent that
the indemnifying party is actually prejudiced by such failure to give notice. In
case any such action is brought against an indemnified party, unless in the
opinion of the indemnified party's counsel a conflict of interest between such
indemnified and indemnifying parties may exist in respect of such claim, the
indemnifying party shall be entitled to participate in and to assume the defense
thereof, jointly with any other indemnifying party similarly notified, to the
extent that the indemnifying party may wish, with counsel reasonably
satisfactory to such indemnified party, and after notice from the indemnifying
party to such indemnified party of its election so to assume the defense
thereof, the indemnifying party shall not be liable to such indemnified party
for any legal or other expenses subsequently incurred by the latter in
connection with the defense thereof other than reasonable costs of
investigation. No indemnifying party shall, without the consent of the
indemnified party, consent to entry of any judgment or enter into any settlement
of any such action which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from
all liability, or a covenant not to sue, in respect to such claim or litigation.
No indemnified party shall consent to entry of any judgment or enter into any
settlement of any such action the defense of which has been assumed by an
indemnifying party without the consent of such indemnifying party.

                  (d)      OTHER INDEMNIFICATION. Indemnification similar to
that specified in the preceding subdivisions of this Section 2.7 (with
appropriate modifications) shall be given by the Company and each seller of
Registrable Securities (but only if and to the extent required pursuant to the
terms of Section 2.7(b)) with respect to any required registration or other
qualification of securities under any Federal or state law or regulation of any
governmental authority, other than the Securities Act.

                                       9

<PAGE>

                  (e)      INDEMNIFICATION PAYMENTS. The indemnification
required by this Section 2.7 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are
received or expense, loss, damage or liability is incurred.

                  (f)      CONTRIBUTION. If the indemnification provided for in
the preceding subdivision of this Section 2.7 is unavailable to an indemnified
party in respect of any expense, loss, claim, damage or liability referred to
therein, then each indemnifying party, in lieu of indemnifying such indemnified
party, shall contribute to the amount paid or payable by such indemnified party
as a result of such expense, loss, claim, damage or liability (i) in such
proportion as is appropriate to reflect the relative benefits received by the
Company on the one hand and the holder or underwriter, as the case may be, on
the other from the distribution of the Registrable Securities or (ii) if the
allocation provided by clause (i) above is not permitted by applicable law, in
such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company on
the one hand and of the holder or underwriter, as the case may be, on the other
in connection with the statements or omissions which resulted in such expense,
loss, damage or liability, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand
and the holder or underwriter, as the case may be, on the other in connection
with the distribution of the Registrable Securities shall be deemed to be in the
same proportion as the total net proceeds received by the Company from the
initial sale of the Registrable Securities by the Company to the purchasers bear
to the gain, if any, realized by all selling holders participating in such
offering or the underwriting discounts and commissions received by the
underwriter, as the case may be. The relative fault of the Company on the one
hand and of the holder or underwriter, as the case may be, on the other shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or omission to state a material fact relates
to information supplied by the Company, by the holder or by the underwriter and
the parties' relative intent, knowledge, access to information supplied by the
Company, by the holder or by the underwriter and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission, provided that the foregoing contribution agreement shall
not inure to the benefit of any indemnified party if indemnification would be
unavailable to such indemnified party by reason of the provisions contained in
the first sentence of subdivision (a) of this Section 2.7, and in no event shall
the obligation of any indemnifying party to contribute under this subdivision
(f) exceed the amount that such indemnifying party would have been obligated to
pay by way of indemnification if the indemnification provided for under
subdivision (b) of this Section 2.7 had been available under the circumstances.

         The Company and the holders of Registrable Securities agree that it
would not be just and equitable if contribution pursuant to this subdivision (f)
were determined by pro rata allocation (even if the holders and any underwriters
were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred
to in the immediately preceding paragraph. The amount paid or payable by an
indemnified party as a result of the losses, claims, damages and liabilities
referred to in the immediately preceding paragraph shall be deemed to include,
subject to the limitations set forth in the preceding sentence and subdivision

                                       10

<PAGE>

(c) of this Section 2.7, any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action
or claim.

         Notwithstanding the provisions of this subdivision (f), no holder of
Registrable Securities or underwriter shall be required to contribute any amount
in excess of the amount by which (i) in the case of any such holder, the net
proceeds received by such holder from the sale of Registrable Securities or (ii)
in the case of an underwriter, the total price at which the Registrable
Securities purchased by it and distributed to the public were offered to the
public exceeds, in any such case, the amount of any damages that such holder or
underwriter has otherwise been required to pay by reason of such untrue or
allege untrue statement or omission. No Person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.

         3.       DEFINITIONS. As used herein, unless the context otherwise
requires, the following terms have the following respective meanings:

                  "AGREEMENT": As defined in Section 1.

                  "COMMISSION": The Securities and Exchange Commission or any
other Federal agency at the time administering the Securities Act.

                  "COMMON STOCK": As defined in Section 1.

                  "COMPANY": As defined in the introductory paragraph of this
Agreement.

                  "DEBENTURE CONVERSION SHARES": As defined in Section 1.

                  "DEBENTURES": As defined in Section 1, such term to include
any securities issued in substitution of or in addition to such Debentures.

                  "EXCHANGE ACT": The Securities Exchange Act of 1934, as
amended, and the rules and regulations of the Commission promulgated thereunder.

                  "PERSON": A corporation, association, partnership, limited
liability company, trust, organization, business, individual, governmental or
political subdivision thereof or a governmental agency.

                  "REGISTRABLE SECURITIES": The Securities and any securities
issued or issuable with respect to such Securities by way of stock dividend or
stock split or in connection with a combination of shares, recapitalization,
merger, consolidation or other reorganization or otherwise. Once issued such
securities shall cease to be Registrable Securities when (a) a registration
statement with respect to the sale of such securities shall have become
effective under the Securities Act and such securities shall have been disposed
of in accordance with such registration statement, (b) they shall have been
distributed to the public pursuant to Rule 144 (or any successor provision)
under the Securities Act, (c) they shall have been otherwise transferred, new
certificates for them not bearing

                                       11

<PAGE>

a legend restricting further transfer shall have been delivered by the Company
and subsequent disposition of them shall not require registration or
qualification of them under the Securities Act or any similar state law then in
force, (d) they shall have ceased to be outstanding, (e) on the expiration of
the applicable Registration Maintenance Period or (f) any and all legends
restricting transfer thereof have been removed in accordance with the provisions
of Rule 144(k) (or any successor provision) under the Securities Act.

                  "REGISTRATION EXPENSES": All expenses incident to the
Company's performance of or compliance with this Agreement, including, without
limitation, all registration, filing and NASD fees, all stock exchange and OTC
Bulletin Board or other NASD or stock exchange listing fees, all fees and
expenses of complying with securities or blue sky laws, all word processing,
duplicating and printing expenses, messenger and delivery expenses, the fees and
disbursements of counsel for the Company and of its independent public
accountants, including the expenses of any special audits or "cold comfort"
letters required by or incident to such performance and compliance, the
reasonable fees and disbursements of not more than one law firm (not to exceed
$20,000) retained by the holder or holders of more than 50% of the Registrable
Securities, premiums and other costs of policies of insurance of the Company
against liabilities arising out of the public offering of the Registrable
Securities being registered and any fees and disbursements of underwriters
customarily paid by issuers or sellers of securities, but excluding underwriting
discounts and commissions and transfer taxes, if any, provided that, in any case
where Registration Expenses are not to be borne by the Company, such expenses
shall not include salaries of Company personnel or general overhead expenses of
the Company, auditing fees, premiums or other expenses relating to liability
insurance required by underwriters of the Company or other expenses for the
preparation of financial statements or other data normally prepared by the
Company in the ordinary course of its business or which the Company would have
incurred in any event.

                  "REGISTRATION MAINTENANCE PERIOD": As defined in Section 2.3.

                  "REQUIRED EFFECTIVENESS DATE": As defined in Section 2.1.

                  "SECURITIES": As defined in Section 1.2.

                  "SECURITIES ACT": The Securities Act of 1933, as amended, and
the rules and regulations of the Commission promulgated thereunder.

                  "SECURITIES PURCHASE AGREEMENT": As defined in Section 1.

                  "SELLERS' REPRESENTATIVE": Richard T. Kiphart or such Person
designated by Richard T. Kiphart as of the time of disposition of the last of
the Debentures held by the Investors (or subsequent Sellers' Representative).

                  "WARRANT SHARES": As defined in Section 1.

         4.       RULE 144. The Company shall timely file the reports required
to be filed by it under the Securities Act and the Exchange Act (including but
not limited to the reports under Sections 13

                                       12

<PAGE>

and 15(d) of the Exchange Act referred to in subparagraph (c) of Rule 144
adopted by the Commission under the Securities Act) and the rules and
regulations adopted by the Commission thereunder (or, if the Company is not
required to file such reports, will, upon the request of any holder of
Registrable Securities, make publicly available other information) and will take
such further action as any holder of Registrable Securities may reasonably
request, all to the extent reasonably required from time to time to enable such
holder to sell Registrable Securities without registration under the Securities
Act within the limitation of the exemptions provided by (a) Rule 144 under the
Securities Act, as such Rule may be amended from time to time, or (b) any
similar rule or regulation hereafter adopted by the Commission. Upon the request
of any holder of Registrable Securities, the Company will deliver to such holder
a written statement as to whether it has complied with the requirements of this
Section 4.

         5.       AMENDMENTS AND WAIVERS. This Agreement may be amended and the
Company may take any action herein prohibited, or omit to perform any act herein
required to be performed by it, only if the Company shall have obtained the
written consent to such amendment, action or omission to act, of the holder or
holders of the sum of 51% or more of the shares of (i) Registrable Securities
issued at such time, plus (ii) Registrable Securities issuable upon exercise or
conversion of the Securities then constituting derivative securities (if such
Securities were not fully exchanged or converted in full as of the date such
consent if sought). Each holder of any Registrable Securities at the time or
thereafter outstanding shall be bound by any consent authorized by this Section
5, whether or not such Registrable Securities shall have been marked to indicate
such consent.

         6.       NOMINEES FOR BENEFICIAL OWNERS. In the event that any
Registrable Securities are held by a nominee for the beneficial owner thereof,
the beneficial owner thereof may, at its election, be treated as the holder of
such Registrable Securities for purposes of any request or other action by any
holder or holders of Registrable Securities pursuant to this Agreement or any
determination of any number of percentage of shares of Registrable Securities
held by an holder or holders of Registrable Securities contemplated by this
Agreement. If the beneficial owner of any Registrable Securities so elects, the
Company may require assurances reasonably satisfactory to it of such owner's
beneficial ownership of such Registrable Securities.

         7.       NOTICES. Except as otherwise provided in this Agreement, all
notices, requests and other communications to any Person provided for hereunder
shall be in writing and shall be given to such Person (a) in the case of a party
hereto other than the Company, addressed to such party in the manner set forth
in the Securities Purchase Agreement or at such other address as such party
shall have furnished to the Company in writing, or (b) in the case of any other
holder of Registrable Securities, at the address that such holder shall have
furnished to the Company in writing, or, until any such other holder so
furnishes to the Company an address, then to and at the address of the last
holder of such Registrable Securities who has furnished an address to the
Company, or (c) in the case of the Company, at the address set forth on the
signature page hereto, to the attention of its President, or at such other
address, or to the attention of such other officer, as the Company shall have
furnished to each holder of Registrable Securities at the time outstanding. Each
such notice, request or other communication shall be effective (i) if given by
mail, four (4) days after such communication is deposited in the United States
mails with first class postage prepaid, addressed as aforesaid or (ii) if given
by any other means (including, without limitation, by fax or air courier),

                                       13

<PAGE>

when delivered at the address specified above, provided that any such notice,
request or communication shall not be effective until received.

         8.       ASSIGNMENT. This Agreement shall be binding upon and inure to
the benefit of and be enforceable by the parties hereto. In addition, and
whether or not any express assignment shall have been made, the provisions of
this Agreement which are for the benefit of the parties hereto other than the
Company shall also be for the benefit of and enforceable by any subsequent
holder of any Registrable Securities. Each of the holders of the Registrable
Securities agrees, by accepting any portion of the Registrable Securities after
the date hereof, to the provisions of this Agreement including, without
limitation, appointment of the Sellers' Representative to act on behalf of such
holder pursuant to the terms hereof which such actions shall be made in the good
faith discretion of the Sellers' Representative and be binding on all persons
for all purposes.

         9.       DESCRIPTIVE HEADINGS. The descriptive headings of the several
sections and paragraphs of this Agreement are inserted for reference only and
shall not limit or otherwise affect the meaning hereof.

         10.      GOVERNING LAW. THIS AGREEMENT SHALL BE CONSTRUED AND ENFORCED
IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE LAWS
OF THE STATE OF MASSACHUSETTS WITHOUT REFERENCE TO THE PRINCIPLES OF CONFLICTS
OF LAWS.

         11.      COUNTERPARTS. This Agreement may be executed by facsimile and
may be signed simultaneously in any number of counterparts, each of which shall
be deemed an original, but all such counterparts shall together constitute one
and the same instrument.

         12.      ENTIRE AGREEMENT. This Agreement embodies the entire agreement
and understanding between the Company and each other party hereto relating to
the subject matter hereof and supercedes all prior agreements and understandings
relating to such subject matter.

         13.      SEVERABILITY. If any provision of this Agreement, or the
application of such provisions to any Person or circumstance, shall be held
invalid, the remainder of this Agreement, or the application of such provision
to Persons or circumstances other than those to which it is held invalid, shall
not be affected thereby.

                            [SIGNATURE PAGE FOLLOWS]

                                       14

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed and delivered by their respective officers thereunto duly authorized as
of the date first above written.

                                   BOSTON BIOMEDICA, INC.

                                       By:          /s/ Kevin W. Quinlan
                                       Name:        Kevin W. Quinlan
                                       Title:       President
                                       Address:     Boston Biomedica, Inc.
                                                    75 West Street
                                                    Bridgewater, Ma 02379

                                                    Fax:     (508) 580-1110
                                                    Tel.:    (508) (580) 1900

                                   SHORELINE MICRO-CAP FUND, L.P.

                                       By:          /s/ Richard P. Kiphart
                                       Name:        Richard P. Kiphart
                                       Title:       Partner

                                       Address:     c/o William Blair & Company
                                       222 West Adams Street
                                                    Chicago, IL 60606
                                                    Fax:     312-368-9418
                                                    Tel.:    312-364-8420

                                       /s/ Richard P. Kiphart
                                       Name: Richard P. Kiphart

                                       15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]